Full-Time

Clinical Transition Educator / RN

Dallas, GA

Posted on 11/1/2025

Option Care Health

Option Care Health

1,001-5,000 employees

Largest independent home infusion therapy provider

No salary listed

Dallas, GA, USA

In Person

Category
Training
Requirements
  • Active and unrestricted Registered Nurse (RN) license required.
  • Minimum of 2 years of experience in the healthcare industry.
  • Experience establishing and maintaining relationships with individuals at all levels of the organization in the business community and with vendors.
  • Experience applying knowledge of standard practices for all services offered as well as current relevant and applicable standards (i.e. ACHC, URAC standards).
  • Experience providing customer service to internal and external customers, including meeting quality standards of services, and evaluation of customer satisfaction.
  • Basic PC skills: Able to competently use internet, email, Microsoft Word, Microsoft Excel, Microsoft PowerPoint
  • Experience in identifying operational issues and recommending and implementing strategies to resolve and improve processes.
  • Access to a reliable means of transportation which will enable the incumbents to travel to care facilities, home visits and multiple hospitals. If such means of transportation would include a personal vehicle, a valid driver’s license and proof of insurance would be required.
  • Willingness to obtain nursing licensure in additional states if business need supports and geography aligns with market.
  • Able to plan, organize and make presentations.
  • 100% local travel to and from partnerships facilities, community hospitals, and medical practice offices to sell Option Care Services, process referrals and provide live education and training support to patient/caregiver and referral sources.
Responsibilities
  • Evaluate, educate, and train patients, caregivers, and facility staff about how OCH services & products will be facilitated in an alternative site, in-home, or virtually in order to ensure successful transition of patients to an Option Care Health delivery model.
  • Conduct patient assessments and evaluations to determine patient viability to join the OCH care delivery model.
  • Partner with, and coordinate with the OCH sales team to understand clinical transition educational needs, and to develop improvements aimed at increasing patient transition volume.
  • Maintains confidentiality of patient and proprietary information and observes legal guidelines for safeguarding the confidentiality of patient and proprietary Option Care information.
  • Provides proper documentation of education utilizing OCH applications and technology.
  • Coordinates the transition of patients from hospital to home or alternate care settings by collaborating with facility staff, providers, and internal teams to ensure timely discharge, therapy education, and continuity of care.
  • Provides in-person patient and caregiver education, gathers pre-admission and insurance information, and facilitates the initiation of services to support safe and effective care at home.
Desired Qualifications
  • Hands on home or alternate site infusion or discharge planning experience
  • Experience growing service provider partnerships

Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Norfolk, Virginia

Founded

1979

Simplify Jobs

Simplify's Take

What believers are saying

  • Analyst price targets up to $40.09 suggest 46% upside from May levels.
  • Expanded $850M credit facility enables M&A consolidation in fragmented market.
  • Management projects $7B revenue by 2029 assuming CID reset normalizes.

What critics are saying

  • Chronic Inflammatory Disease portfolio headwind of $55M persists beyond 2026.
  • Revenue growth slowed to 1.1% versus historical 12% and industry 4.7%.
  • Biosimilar conversions and IRA headwinds compress margins $25–35M annually through 2027.

What makes Option Care Health unique

  • Largest independent home infusion provider with 315,000+ unique patients served.
  • 40% of claims processed without human intervention via automation investments.
  • Diversified portfolio across acute, chronic, and immunoglobulin neurology therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Time Off

Bonding Time Off

401(k) Retirement Plan

401(k) Company Match

Health Savings Account/Flexible Spending Account

Flexible Spending Accounts

Tuition Reimbursement

Family Support

Mental Health Support

Company Paid Life Insurance

Award/Recognition Programs

Company News

Simply Wall St
Apr 4th, 2026
Option Care Health expands credit facility to $850M, boosts buyback to $1B

Option Care Health has expanded its revolving credit facility by $450 million to $850 million and increased its share repurchase authorisation to $1 billion, whilst reaffirming its 2026 guidance. The moves strengthen liquidity and signal management confidence in cash generation. The expanded buyback and credit facility provide greater flexibility for growth investments and capital returns, though near-term focus remains on executing guidance and managing reimbursement pressures. The company's narrative projects $7 billion revenue and $302.2 million earnings by 2029, implying 7.5% annual revenue growth. Analyst fair value estimates range widely from $3.66 to $40.09 per share, with the upper estimate suggesting 46% upside from current prices.

MicroCare
Mar 9th, 2026
MicroCare Medical welcomes Matt Lingenfelter as national sales manager, healthcare.

MicroCare Medical welcomes Matt Lingenfelter as national sales manager, healthcare. March 09, 2026 MicroCare Medical is pleased to welcome Matt Lingenfelter as national sales manager, healthcare. With more than 20 years of experience in healthcare sales and leadership, Matt will help drive national growth and strengthen partnerships for the MicroCare Medical instrument care and infection prevention solutions. In this role, Matt will guide healthcare sales strategy across the U.S., focusing on expanding key accounts, building strong distributor relationships, and supporting the sales team. He will also work closely with marketing, operations, and product development to ensure MicroCare continues delivering solutions that meet the evolving needs of healthcare professionals. Before joining MicroCare, Matt held leadership roles with Option Care Health, Belimed, and Aesculap, where he developed deep expertise in surgical instrumentation, endoscopic technologies, and hospital system support. "Matt's experience and understanding of healthcare systems make him a fantastic addition to our team," said Ray Bellavance, vice president of global sales and marketing at MicroCare. "We're excited to have him help grow our healthcare business and strengthen partnerships across the country."

Yahoo Finance
Feb 27th, 2026
Option Care Health posts 13% revenue growth despite $25M–35M Stelara biosimilar headwind

Option Care Health reported a 13% revenue increase in Q4 2025, with acute therapies growing in the mid-teens and chronic therapies in the low double digits. The company served over 315,000 unique patients and improved operational efficiency, with 40% of claims now processed without human intervention. For 2026, the company issued revenue guidance of $5.8 billion to $6 billion, incorporating a 400 basis point headwind from Stelara biosimilar conversions and Inflation Reduction Act impacts. Adjusted EBITDA is projected at $480 million to $505 million, accounting for a $25 million to $35 million gross profit headwind from Stelara transitions. Operating cash flow is expected to exceed $340 million, representing over 30% growth. The company plans to launch at least two new pharmaceutical manufacturer programmes and expand its infusion clinic model to support higher-acuity therapies.

PREEMPT, Inc
Sep 30th, 2025
EEOC Sues Option Care Health, Inc. for Pregnancy Discrimination

EEOC sues Option Care Health, Inc. for pregnancy discrimination.

Option Care Health
Aug 7th, 2025
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

Quince Therapeutics selects Option Care Health as specialty infusion therapy provider for administration of lead asset eDSP.

INACTIVE